vs
Side-by-side financial comparison of COLLEGIUM PHARMACEUTICAL, INC (COLL) and Citi Trends Inc (CTRN). Click either name above to swap in a different company.
COLLEGIUM PHARMACEUTICAL, INC is the larger business by last-quarter revenue ($205.4M vs $197.1M, roughly 1.0× Citi Trends Inc). COLLEGIUM PHARMACEUTICAL, INC runs the higher net margin — 8.3% vs -3.5%, a 11.8% gap on every dollar of revenue. On growth, COLLEGIUM PHARMACEUTICAL, INC posted the faster year-over-year revenue change (12.9% vs 10.1%). COLLEGIUM PHARMACEUTICAL, INC produced more free cash flow last quarter ($122.4M vs $767.0K). Over the past eight quarters, COLLEGIUM PHARMACEUTICAL, INC's revenue compounded faster (19.1% CAGR vs -4.3%).
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative, abuse-deterrent pain management therapies. Operating primarily in the U.S. market, it offers extended-release analgesics for chronic pain patients, serving providers across primary and specialty care segments.
Citi Trends, Inc. is an American retail clothing chain selling discounted products targeted primarily at African-American customers.
COLL vs CTRN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $205.4M | $197.1M |
| Net Profit | $17.0M | $-6.9M |
| Gross Margin | 62.5% | — |
| Operating Margin | 29.6% | -3.7% |
| Net Margin | 8.3% | -3.5% |
| Revenue YoY | 12.9% | 10.1% |
| Net Profit YoY | 35.3% | 3.6% |
| EPS (diluted) | $0.48 | $-0.86 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $205.4M | $197.1M | ||
| Q3 25 | $209.4M | $190.8M | ||
| Q2 25 | $188.0M | $201.7M | ||
| Q1 25 | $177.8M | $211.2M | ||
| Q4 24 | $181.9M | $179.1M | ||
| Q3 24 | $159.3M | $176.6M | ||
| Q2 24 | $145.3M | $186.3M | ||
| Q1 24 | $144.9M | $215.2M |
| Q4 25 | $17.0M | $-6.9M | ||
| Q3 25 | $31.5M | $3.8M | ||
| Q2 25 | $12.0M | $871.0K | ||
| Q1 25 | $2.4M | $-14.2M | ||
| Q4 24 | $12.5M | $-7.2M | ||
| Q3 24 | $9.3M | $-18.4M | ||
| Q2 24 | $19.6M | $-3.4M | ||
| Q1 24 | $27.7M | $3.6M |
| Q4 25 | 62.5% | — | ||
| Q3 25 | 61.7% | — | ||
| Q2 25 | 57.7% | — | ||
| Q1 25 | 54.8% | — | ||
| Q4 24 | 54.0% | — | ||
| Q3 24 | 60.8% | — | ||
| Q2 24 | 62.5% | — | ||
| Q1 24 | 63.1% | — |
| Q4 25 | 29.6% | -3.7% | ||
| Q3 25 | 29.7% | 1.8% | ||
| Q2 25 | 18.7% | 0.2% | ||
| Q1 25 | 12.2% | 0.6% | ||
| Q4 24 | 20.9% | -4.9% | ||
| Q3 24 | 21.9% | -14.1% | ||
| Q2 24 | 32.7% | -3.7% | ||
| Q1 24 | 34.1% | 1.8% |
| Q4 25 | 8.3% | -3.5% | ||
| Q3 25 | 15.0% | 2.0% | ||
| Q2 25 | 6.4% | 0.4% | ||
| Q1 25 | 1.4% | -6.7% | ||
| Q4 24 | 6.9% | -4.0% | ||
| Q3 24 | 5.9% | -10.4% | ||
| Q2 24 | 13.5% | -1.8% | ||
| Q1 24 | 19.1% | 1.7% |
| Q4 25 | $0.48 | $-0.86 | ||
| Q3 25 | $0.84 | $0.46 | ||
| Q2 25 | $0.34 | $0.11 | ||
| Q1 25 | $0.07 | $-1.70 | ||
| Q4 24 | $0.36 | $-0.86 | ||
| Q3 24 | $0.27 | $-2.21 | ||
| Q2 24 | $0.52 | $-0.42 | ||
| Q1 24 | $0.71 | $0.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $386.7M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $301.7M | $107.8M |
| Total Assets | $1.7B | $464.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $386.7M | — | ||
| Q3 25 | $285.9M | — | ||
| Q2 25 | $222.2M | — | ||
| Q1 25 | $197.8M | — | ||
| Q4 24 | $162.8M | — | ||
| Q3 24 | $120.0M | — | ||
| Q2 24 | $271.6M | — | ||
| Q1 24 | $318.0M | — |
| Q4 25 | $301.7M | $107.8M | ||
| Q3 25 | $274.8M | $113.2M | ||
| Q2 25 | $232.2M | $108.6M | ||
| Q1 25 | $234.4M | $113.2M | ||
| Q4 24 | $228.8M | $130.3M | ||
| Q3 24 | $234.3M | $136.6M | ||
| Q2 24 | $216.6M | $154.8M | ||
| Q1 24 | $222.2M | $157.7M |
| Q4 25 | $1.7B | $464.3M | ||
| Q3 25 | $1.6B | $457.4M | ||
| Q2 25 | $1.6B | $437.4M | ||
| Q1 25 | $1.6B | $462.8M | ||
| Q4 24 | $1.7B | $467.1M | ||
| Q3 24 | $1.6B | $506.7M | ||
| Q2 24 | $1.1B | $484.1M | ||
| Q1 24 | $1.1B | $518.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $123.0M | $8.6M |
| Free Cash FlowOCF − Capex | $122.4M | $767.0K |
| FCF MarginFCF / Revenue | 59.6% | 0.4% |
| Capex IntensityCapex / Revenue | 0.3% | 4.0% |
| Cash ConversionOCF / Net Profit | 7.25× | — |
| TTM Free Cash FlowTrailing 4 quarters | $327.6M | $11.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $123.0M | $8.6M | ||
| Q3 25 | $78.4M | $3.9M | ||
| Q2 25 | $72.4M | $-11.0M | ||
| Q1 25 | $55.4M | $28.5M | ||
| Q4 24 | $84.6M | $-18.4M | ||
| Q3 24 | $-9.0M | $5.6M | ||
| Q2 24 | $67.4M | $-19.6M | ||
| Q1 24 | $61.9M | $23.3M |
| Q4 25 | $122.4M | $767.0K | ||
| Q3 25 | $78.3M | $-1.7M | ||
| Q2 25 | $72.4M | $-13.1M | ||
| Q1 25 | $54.6M | $26.0M | ||
| Q4 24 | $84.1M | $-20.4M | ||
| Q3 24 | $-9.2M | $1.7M | ||
| Q2 24 | $67.1M | $-21.2M | ||
| Q1 24 | $61.4M | $20.0M |
| Q4 25 | 59.6% | 0.4% | ||
| Q3 25 | 37.4% | -0.9% | ||
| Q2 25 | 38.5% | -6.5% | ||
| Q1 25 | 30.7% | 12.3% | ||
| Q4 24 | 46.2% | -11.4% | ||
| Q3 24 | -5.8% | 0.9% | ||
| Q2 24 | 46.2% | -11.4% | ||
| Q1 24 | 42.3% | 9.3% |
| Q4 25 | 0.3% | 4.0% | ||
| Q3 25 | 0.1% | 2.9% | ||
| Q2 25 | 0.0% | 1.0% | ||
| Q1 25 | 0.4% | 1.2% | ||
| Q4 24 | 0.3% | 1.1% | ||
| Q3 24 | 0.2% | 2.2% | ||
| Q2 24 | 0.2% | 0.9% | ||
| Q1 24 | 0.4% | 1.5% |
| Q4 25 | 7.25× | — | ||
| Q3 25 | 2.49× | 1.01× | ||
| Q2 25 | 6.05× | -12.59× | ||
| Q1 25 | 22.92× | — | ||
| Q4 24 | 6.75× | — | ||
| Q3 24 | -0.96× | — | ||
| Q2 24 | 3.44× | — | ||
| Q1 24 | 2.23× | 6.56× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
